Pacira BioSciences (NASDAQ:PCRX) Stock Rating Reaffirmed as Hold by Needham & Company LLC

Pacira BioSciences (NASDAQ:PCRX)‘s stock had its “hold” rating reiterated by research analysts at Needham & Company LLC in a report released on Thursday, Benzinga reports.

Several other equities analysts have also weighed in on PCRX. HC Wainwright restated a “buy” rating and issued a $38.00 price objective on shares of Pacira BioSciences in a report on Wednesday, July 1st. Oppenheimer started coverage on shares of Pacira BioSciences in a research note on Wednesday, September 23rd. They issued an “outperform” rating and a $32.00 price objective on the stock. Royal Bank Of Canada lifted their target price on shares of Pacira BioSciences from $24.00 to $25.00 and gave the stock a “sector perform” rating in a report on Wednesday, August 5th. Truist Financial upped their target price on shares of Pacira BioSciences from $30.00 to $31.00 and gave the company a “buy” rating in a research report on Wednesday. Finally, Weiss Ratings downgraded Pacira BioSciences from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, September 16th. Three equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $30.29.

Pacira BioSciences Trading Up 44.0%

NASDAQ:PCRX traded up $11.09 on Thursday, hitting $36.28. 18,125,437 shares of the stock were exchanged, compared to its average volume of 749,122. The stock has a market capitalization of $1.45 billion, a price-to-earnings ratio of 103.67 and a beta of 0.25. Pacira BioSciences has a 52 week low of $18.80 and a 52 week high of $36.33. The company has a debt-to-equity ratio of 0.54, a quick ratio of 3.94 and a current ratio of 5.04. The company’s 50-day moving average price is $25.18 and its 200 day moving average price is $24.41.

Pacira BioSciences (NASDAQ:PCRX) last released its earnings results on Tuesday, August 4th. The company reported $0.73 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.08. The company had revenue of $192.40 million for the quarter, compared to the consensus estimate of $191.06 million. Pacira BioSciences had a net margin of 1.96% and a return on equity of 9.68%. The company’s revenue was up 6.2% compared to the same quarter last year. During the same period in the prior year, the company posted $0.74 EPS. On average, equities research analysts forecast that Pacira BioSciences will post 1.91 earnings per share for the current year.

Insider Buying and Selling at Pacira BioSciences

In related news, insider Jonathan Slonin sold 3,040 shares of Pacira BioSciences stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $23.23, for a total transaction of $70,619.20. Following the transaction, the insider owned 216,384 shares of the company’s stock, valued at $5,026,600.32. This trade represents a 1.39% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Pacira BioSciences

Several large investors have recently bought and sold shares of PCRX. Meeder Asset Management Inc. bought a new position in shares of Pacira BioSciences during the first quarter worth $46,000. Global Retirement Partners LLC bought a new stake in shares of Pacira BioSciences in the 2nd quarter valued at $51,000. State of Wyoming bought a new stake in shares of Pacira BioSciences in the 2nd quarter valued at $78,000. PNC Financial Services Group Inc. raised its stake in Pacira BioSciences by 15.1% during the 1st quarter. PNC Financial Services Group Inc. now owns 3,751 shares of the company’s stock worth $85,000 after buying an additional 492 shares during the period. Finally, Keating Financial Advisory Services Inc. acquired a new stake in Pacira BioSciences during the 2nd quarter worth $110,000. Institutional investors own 99.73% of the company’s stock.

Pacira BioSciences News Summary

Here are the key news stories impacting Pacira BioSciences this week:

• Positive Sentiment: Viatris agreed to acquire Pacira for $36.50 per share in cash, valuing the company at approximately $1.65 billion. The deal gives shareholders a defined cash exit and adds Pacira’s EXPAREL and ZILRETTA non-opioid pain medicines to Viatris’ portfolio. The transaction is expected to close by the end of 2026, subject to customary conditions and approvals. Viatris acquisition announcement
• Positive Sentiment: Viatris said the acquisition will strengthen its U.S. innovative-medicines and global research capabilities, expand the reach of Pacira’s products, and complement its fast-acting meloxicam opportunity. These anticipated synergies helped support investor interest. Viatris to buy Pacira
• Neutral Sentiment: Pacira’s shares are trading close to the $36.50 offer, leaving limited deal-related upside unless another bidder emerges or Viatris raises its proposal. Trading was temporarily halted pending the acquisition news. Pacira to be acquired by Viatris
• Neutral Sentiment: Halper Sadeh LLC announced an investigation into whether Pacira’s board obtained a fair price and adequately represented shareholders. Such investigations can create deal-process uncertainty but do not necessarily indicate that the transaction will fail. Shareholder investigation
• Negative Sentiment: Before the takeover announcement, Zacks downgraded PCRX to “strong sell,” while Truist raised its target to $31 but maintained a price target below the offer price. Those views are now less relevant to the stock’s near-term valuation because the acquisition establishes a cash reference price.

About Pacira BioSciences

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain-management products. The company’s portfolio is designed to help manage acute and chronic pain while reducing reliance on traditional opioid therapies.

Its principal product is EXPAREL, an extended-release formulation of bupivacaine used to provide postsurgical pain relief. Pacira also markets ZILRETTA, an extended-release corticosteroid injection for osteoarthritis-related knee pain, and the iovera° system, a handheld cryoanalgesia device intended to temporarily block peripheral nerves and provide targeted pain relief.

Originally known as Pacira Pharmaceuticals, the company adopted the name Pacira BioSciences in 2018 to reflect its broader focus on innovative therapies and technologies.